SCHEMBL2270880

SCHEMBL2270880

O=C(Nc1cc(CCc2ccccc2)ccc1C(=O)O)c1ccccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.60
HTT P42858 4/20 0.53
LMNA P02545 4/20 0.53
NPC1 O15118 2/20 0.53
TP53 P04637 2/20 0.53
GAA P10253 1/20 0.53
HSD17B10 Q99714 4/20 0.51
HPGD P15428 3/20 0.51
ALDH1A1 P00352 2/20 0.51
TSHR P16473 2/20 0.51
MAPT P10636 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NLRP1 Q9C000 1/20 0.51
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HCAR2 Q8TDS4 2/20 0.48
KCNMA1 Q12791 1/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276177 0.85 SLC16A3 (0.55) GAAHPGDALDH1A1KDM4EKCNMA1
SCHEMBL2276434 0.85 RAB9A (0.55) NPC1GAAALDH1A1MEN1KMT2A
SCHEMBL2275852 0.85 MEN1 (0.55) ALOX15LMNANPC1HPGDALDH1A1
SCHEMBL2275929 0.85 KMT2A (0.62) MAPTMEN1KMT2ATDP1PLK1
SCHEMBL2270925 0.83 PLK1 (0.57) HTTALDH1A1MAPTMEN1KMT2A
SCHEMBL2274245 0.82 LMNA (0.49) HTTLMNANPC1TP53HSD17B10
SCHEMBL2276347 0.82 MEN1 (0.56) LMNAGAAMEN1KMT2ARECQL
SCHEMBL6093021 0.81 LMNA (0.60) HTTLMNANPC1TP53GAA
SCHEMBL2278451 0.81 LTC4S (0.60) ALDH1A1MAPTMEN1KMT2AHCAR2
SCHEMBL4215640 0.81 MEN1 (0.52) MEN1KMT2AHCAR2RECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ALOX15 238/4885HTT 3716/4885LMNA 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.